Compare Fiverr International Ltd (FVRR) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fiverr International Ltd vs TransMedics Group Inc — how do they compare? Fiverr International Ltd trades at $8.71 (market cap $310.61M), while TransMedics Group Inc trades at $77.34 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 8.8× Fiverr International Ltd's market cap, and TransMedics Group Inc is trading nearer its 52-week high, Fiverr International Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fiverr International Ltd for 62 Days and TransMedics Group Inc for 24 Days on average.
| FVRR | TMDX | |
|---|---|---|
Market Cap | $310.61M | $2.74B |
Volume | 381,459 | 949,331 |
Sector | Media | Health |
52-Week High | $23.60 | $150.42 |
52-Week Low | $8.47 | $61.99 |
Typical Hold Time | 62 Days | 24 Days |
Enterprise Value | $63.00M | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fiverr International (FVRR) trades at $8.70, up 2.35% on the day, but remains in a bearish technical trend with resistance near $9.00. Recent Q2 2026 earnings missed estimates, with revenue declining 10% year-over-year to $97.8 million, as AI adoption pressures lower-value freelance demand. The company maintains strong gross margins of 82% and trades at discounted valuations, including a P/E of 10.67 and P/S of 0.76. Cash flow trends show operational strength but negative net cash flow in 2025 and 2026.
The outlook is cautious; while valuations are low and profitability is improving, AI disruption and recent earnings misses pose significant headwinds. Analyst consensus is a 'Hold' with a $10.50 price target, reflecting near-term challenges but potential recovery if growth stabilizes. Key risks include competitive threats from AI tools and execution risks in adapting the business model.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fiverr International Ltd
Fiverr International Ltd is involved in buying and selling digital services in the same fashion as physical goods on an e-commerce platform. It is set out to design a digital marketplace that is built with a comprehensive SKU-like services catalog and a search, finds, and order process that mirrors a typical e-commerce transaction. The service offerings of the company include Graphics and Design, Digital Marketing, Writing and Translation, and Video and Animation among others.
Read more on FVRR →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
